These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31828738)

  • 1. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.
    Ryan M; Donato BMK; Irish W; Gasteyger C; L'Italien G; Laurence J
    Pharmacoeconomics; 2020 Mar; 38(3):307-313. PubMed ID: 31828738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
    Alabdulqader M; Alfakeeh K
    BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O; Falush Y; Davidovits M
    Pediatr Nephrol; 2019 Dec; 34(12):2601-2604. PubMed ID: 31520126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates.
    Kumar G; Al-Masri O; Alismaili Z; Tawfik E; Al-Ghabra MK; Ilyas SH; Al-Khasawneh E
    J Paediatr Child Health; 2019 Oct; 55(10):1237-1240. PubMed ID: 30714243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for atypical haemolytic uraemic syndrome.
    Pugh D; O'Sullivan ED; Duthie FA; Masson P; Kavanagh D
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012862. PubMed ID: 33783815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA; Verhave JC; Adang EM; Wetzels JF
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
    Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy.
    Neave L; Gale DP; Cheesman S; Shah R; Scully M
    Br J Haematol; 2019 Jul; 186(1):113-124. PubMed ID: 30916388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R; San A; Kurtkoti J; Parnham A
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():32-35. PubMed ID: 28176475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
    Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
    Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA; Rahim KA; Faqeehi HY; Alanazi A
    Kidney Blood Press Res; 2020; 45(6):939-954. PubMed ID: 33238263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.